[Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases]. / Traitement de la fièvre hémorragique argentine par le plasma de convalescent. 4,433 cas.

During the 23 consecutive annual epidemics of Argentine haemorrhagic fever observed from 1959 to 1983, a group of 4,433 patients were treated at Junin (Argentina) with convalescent's plasma; the overall mortality rate was 3.29%. In 1958, before convalescent's plasma was used, the mortality rate in 448 patients who received the conventional treatment was 42.85%. The difference between the two groups is highly significant and demonstrates the value of convalescent's plasma in the treatment of the disease.

HIV-1 infection in intravenous drug abusers with clinical manifestations of hepatitis in the city of Buenos Aires.

A serologic study of hepatitis and HIV infections among 99 I.V. drug abusers with hepatitis was conducted between December 1986 and September 1987. The average age of the study subjects was 21 years. Eighty-nine (90%) of the subjects were male, including four whose sexual orientation was homosexual/bisexual. Serologic tests indicated that 87 of the 99 subjects had hepatitis B virus infections, 62 acute and 25 chronic. Nine (10%) of these 87 patients were coinfected with the delta agent. Two subjects had acute cases of hepatitis A, and the 10 remaining subjects had non-A non-B hepatitis. Forty-seven of the study subjects were also found to be infected with HIV-1. The prevalence of the delta marker was surprisingly high, because Argentina has been regarded as nonendemic for the delta virus. Given the trend of increasing I.V. drug abuse in Argentina, these results presage a significant increase in the delta agent's prevalence in the immediate future.

[Treatment of neurological forms of Argentinian hemorrhagic fever with cytarabine]. / Traitement des formes nerveuses de la fièvre hémorragique argentine par la cytarabine.

The effects of cytarabine on neurological forms of Argentina Hemorrhagic Fever were evaluated in 125 patients. The mortality was 12.88 per cent compared to 61.40 per cent in untreated patients. (p less than 0.0001). The efficiency of this treatment depends on its early application. No side effect was observed.

Prevalencia de infección por HTLV-I/II en donantes de sangre de la Provincia de Santa Fe, Argentina / Prevalence of HTLV-I/II infection among blood donors in Santa Fe Province, Argentina

Subsequent to the National Epidemiologic Surveillance Program developed in 1997 by the National AIDS Program, anti-HTLV-I/II antibodies among blood donors in Santa Fe Province started to be detected. On the basis of this initial finding, it was regarded of interest to evaluate the true HTLV-I/II seroprevalence in this population during a four-year survey. Thus, from 1997 up to 2002, 9425 samples were studied from 17 out of the 19 provincial departments. Out of the total sampling, 38 proved reactive by agglutination techniques, 18 of which were confirmed by western blot (WB). Out of the latter, 10 were HTLV-I/II seropositive with a final prevalence of 0.1% (10/9425), whereas 7 were indeterminate and 1 negative. Among these 10 confirmed sera, 2 (0.02%) were HTLV, 3 (0.03%) HTLV-I and 5 (0.05%) HTLV-II. It should be highlighted that the presence of HTLV-I/II infection in blood donors in Santa Fe Province was demonstrated for the first time, with a prevalence greater than that reported for blood donors in non-endemic Argentine areas. Such findings confirm the need of corresponding systematic screening through regulatory blood bank norms in Santa Fe Province.

Subsecuentemente a que en 1997 el Programa Nacional de SIDA implementó un Programa de Vigilancia Epidemiológica a escala nacional, se comenzaron a detectar anticuerpos anti-HTLV-I/II en donantes de sangre de la Provincia de Santa Fe. En base a ese hallazgo inicial, se consideró pertinenteestimar la seroprevalencia de HTLV-I/II en donantes santafecinos en el curso de los 4 años siguientes. Así,desde 1997 hasta 2002, se estudiaron 9425 muestras provenientes de 17 de los 19 departamentos de laProvincia. Del total de muestras, 38 resultaron reactivas por técnicas de tamizaje, y de ellas 18 fueron confirmadas por western blot (WB). De esas muestras, 10 fueron HTLV-I/II seropositivas con una prevalencia finalde 0.1% (10/9425), en tanto que 7 resultaron indeterminadas y 1 negativa. De las seropositivas, 2 (0.02 %)eran HTLV, 3 (0.03 %) HTLV-I, y 5 (0.05 %) HTLV-II. Cabe destacar que por primera vez se constató lapresencia de infección por HTLV-I/II en donantes de sangre de Santa Fe, y con una prevalencia mayor a lasreferidas para donantes de sangre de áreas no endémicas de Argentina. Estos datos fundamentan la necesidadde un screening sistemático para la infección por HTLV-I/II mediante normas regulatorias en bancos desangre de esta provincia..

Factores de riesgo de infección por el virus de la inmunodeficiencia humana tipo 1 en un grupo de mujeres de Buenos Aires / Risk factors of infection by human inmunodeficiency virus type 1 in a women group of Buenos Aires city

Se estudiaron 204 mujeres de la ciudad de Buenos Aires, con el objeto de determinar los factores de riesgo de infección por el virus de la inmunodeficiencia humana tipo 1. Se recogieron datos epidemiológicos sobre factores de riesgo y se realizó un estudio serológico en muestras de sangre tomadas en el momento de la admisión. Las mujeres adictas a drogas por vía endovenosa tuvieron una tasa de infección del 65,85 por ciento, 8 veces superior al de las no adictas; esta tasa se elevó al 90,62 por ciento en aquellas mujeres que además tenían contactos sexuales con hombres seropositivos para el virus de la inmunodeficiencia humana tipo 1. En 7 casos registrados de transfusión sanguínea como único factor de riesgo reconocido, uno solo fue seropositivo. En este estudio, de las 64 pacientes con serología positiva el 84,37 por ciento de ellas eran drogadictas endovenosas, confirmando nuevamente que la drogadicción endovenosa fue el factor de mayor riesgo de infección por el virus de la inmunodeficiencia humana tipo 1